Atopic Dermatitis

In a recent phase 3 trial, dupilumab (Dupixent, Sanofi and Regeneron) demonstrated positive results in itch reduction, skin clearance and quality-of-life. Indicating the biologic as a viable treatment option for severe atopic dermatitis in younger children.

A recent review reveals older adults are underrepresented in trials investigating systemic immunomodulators as a treatment for atopic dermatitis.

Adults with atopic dermatitis (AD) stay on dupilumab (Dupixent, Sanofi and Regeneron) significantly longer than on cyclosporine, according to a recent study.

Across all doses, lebrikizumab showed significant dose-dependent improvement in primary study endpoints for improvements in atopic dermatitis, according to data from phase 2b trials.

In clinical trials, most patients treated with tralokinumab maintained 75% reductions in EASI scores for one year.

Vehicles for topical atopic dermatitis treatments deliver benefits that promote barrier restoration and enhance innate immune defenses, a review suggests.

Tape strips outperformed skin biopsies by differentiating eczema from psoriasis with high accuracy, researchers report.

The U.S. Food and Drug Administration (FDA) has granted JAK-inhibitor delgocitinib cream (LEO Pharma) Fast Track Designation for chronic hand eczema.

Gain insight from the experts on current and future treatment for pediatric atopic dermatitis.

The U.S. Food and Drug administration has accepted the Biologics License Application for tralokinumab (LEO Pharma) for moderate-to-severe atopic dermatitis and is expected to make a decision in the second quarter of 2021.